MedTrace Logo

A Study of Tor Kinase Inhibitor in Advanced Tumors

NCT00731263 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2012-07-11

No results posted yet for this study

Summary

The purpose of the study is to assess the safety, tolerability and pharmacokinetics of AZD8055 and determine the maximum tolerated dose to take into phase II trials.

Conditions

Interventions

DRUG

AZD8055

Oral solution or tablet, single dose on Day 1 Part A, twice daily ascending dosing from day 8 onwards (until maximum tolerated dose is reached), cycles of 28 days treatment.

Sponsors & Collaborators

Principal Investigators

  • Prof Stan Kaye · Royal Marsden Hospital, Sutton, Surrey, England, SM2 5PT

  • Dr Carol Aghajanian · Memorial Sloan-Kettering Cancer Centre, 1275 York Avenue, New York, NY 10065, USA

  • Dr Aung Naing · MD Anderson Cancer Centre, 1515 Holcombe Blvd, Houston, Texas, USA

  • Professor Eric Raymond · Hôpital Beaujon, 100, Boulevard du Général Leclerc, 92118 Clichy Cedex, France

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2010-11-30
Completion
2010-11-30

Countries

  • United States
  • France
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00731263 on ClinicalTrials.gov